{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:34:07Z","timestamp":1793414047052,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1245\/s10434-023-13907-4","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T18:21:20Z","timestamp":1690395680000},"page":"5951-5961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects"],"prefix":"10.1245","volume":"30","author":[{"given":"Kristin","family":"Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Spring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"O\u2019Riordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"13907_CR1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","volume":"23","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2022","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23:382\u201392.","journal-title":"Lancet Oncol"},{"key":"13907_CR2","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaoncol.2019.1856","volume":"5","author":"NY Yu","year":"2019","unstructured":"Yu NY, Iftimi A, Yau C, Tobin NP, van\u2019t Veer L, Hoadley KA, et al. Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in postmenopausal patients with luminal a or luminal b breast cancer. JAMA Oncol. 2019;5:1304\u20139.","journal-title":"JAMA Oncol"},{"key":"13907_CR3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2022.01.012","volume":"62","author":"I Yussof","year":"2022","unstructured":"Yussof I, Mohd Tahir NA, Hatah E, Mohamed Shah N. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review. Breast. 2022;62:22\u201335.","journal-title":"Breast"},{"key":"13907_CR4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","volume":"126","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529\u201337.","journal-title":"Breast Cancer Res Treat"},{"key":"13907_CR5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet. 2005;365:60\u20132.","journal-title":"Lancet"},{"key":"13907_CR6","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1001\/jama.1981.03310420031025","volume":"245","author":"Y Erlik","year":"1981","unstructured":"Erlik Y, Tataryn IV, Meldrum DR, Lomax P, Bajorek JG, Judd HL. Association of waking episodes with menopausal hot flushes. JAMA. 1981;245:1741\u20134.","journal-title":"JAMA"},{"key":"13907_CR7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(11)70364-3","volume":"13","author":"E Mann","year":"2012","unstructured":"Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13:309\u201318.","journal-title":"Lancet Oncol"},{"key":"13907_CR8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/GME.0000000000000597","volume":"23","author":"NE Avis","year":"2016","unstructured":"Avis NE, Coeytaux RR, Isom S, Prevette K, Morgan T. Acupuncture in Menopause (AIM) study: a pragmatic, randomized controlled trial. Menopause. 2016;23:626\u201337.","journal-title":"Menopause"},{"key":"13907_CR9","doi-asserted-by":"crossref","first-page":"788","DOI":"10.7326\/0003-4819-132-10-200005160-00004","volume":"132","author":"KJ Pandya","year":"2000","unstructured":"Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000;132:788\u201393.","journal-title":"Ann Intern Med"},{"key":"13907_CR10","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","volume":"366","author":"KJ Pandya","year":"2005","unstructured":"Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005;366:818\u201324.","journal-title":"Lancet"},{"key":"13907_CR11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/gme.0b013e31820ccae9","volume":"18","author":"RR Freedman","year":"2011","unstructured":"Freedman RR, Kruger ML, Tancer ME. Escitalopram treatment of menopausal hot flashes. Menopause. 2011;18:893\u20136.","journal-title":"Menopause"},{"key":"13907_CR12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/13697137.2011.586445","volume":"15","author":"P Bouchard","year":"2012","unstructured":"Bouchard P, Panay N, de Villiers TJ, Vincendon P, Bao W, Cheng RJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric. 2012;15:12\u201320.","journal-title":"Climacteric"},{"key":"13907_CR13","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2009.26.6379","volume":"28","author":"DL Barton","year":"2010","unstructured":"Barton DL, LaVasseur BI, Sloan JA, Stawis AN, Flynn KA, Dyar M, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 2010;28:3278\u201383.","journal-title":"J Clin Oncol"},{"key":"13907_CR14","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1001\/jama.295.17.2057","volume":"295","author":"HD Nelson","year":"2006","unstructured":"Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295:2057\u201371.","journal-title":"JAMA"},{"key":"13907_CR15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/GME.0000000000000546","volume":"22","author":"J Carpenter","year":"2015","unstructured":"Carpenter J, Gass ML, Maki PM, Newton KM, Pinkerton JV, Taylor M, Utian WH, Schnatz PF, Kaunitz AM, Shapiro M, Shifren JL. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22:1155\u201372 (quiz 1173\u20134).","journal-title":"Menopause"},{"key":"13907_CR16","doi-asserted-by":"crossref","first-page":"kz088","DOI":"10.1093\/jncics\/pkz088","volume":"4","author":"RA Leon-Ferre","year":"2020","unstructured":"Leon-Ferre RA, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora D, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectr. 2020;4:kz088.","journal-title":"JNCI Cancer Spectr"},{"key":"13907_CR17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","volume":"401","author":"S Lederman","year":"2023","unstructured":"Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401:1091\u2013102.","journal-title":"Lancet"},{"key":"13907_CR18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/2327-6924.12137","volume":"27","author":"AP Handley","year":"2015","unstructured":"Handley AP, Williams M. The efficacy and tolerability of SSRI\/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract. 2015;27:54\u201361.","journal-title":"J Am Assoc Nurse Pract"},{"key":"13907_CR19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000348564","volume":"75","author":"Z Sun","year":"2013","unstructured":"Sun Z, Hao Y, Zhang M. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Investig. 2013;75:255\u201362.","journal-title":"Gynecol Obstet Investig"},{"key":"13907_CR20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/gme.0b013e31826421a8","volume":"20","author":"JV Pinkerton","year":"2013","unstructured":"Pinkerton JV, Constantine G, Hwang E, Cheng R-FJ, Study 3353 Investigators. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause. 2013;20:28\u201337.","journal-title":"Menopause"},{"key":"13907_CR21","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","volume":"356","author":"CL Loprinzi","year":"2000","unstructured":"Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356:2059\u201363.","journal-title":"Lancet"},{"key":"13907_CR22","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1200\/JCO.2010.33.1298","volume":"29","author":"AH Boekhout","year":"2011","unstructured":"Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-T\u00f6ns JH, Adriaansz S, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011;29:3862\u20138.","journal-title":"J Clin Oncol"},{"key":"13907_CR23","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","volume":"2","author":"R Eastell","year":"2016","unstructured":"Eastell R, O\u2019Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069.","journal-title":"Nat Rev Dis Primers"},{"key":"13907_CR24","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jnci\/81.14.1086","volume":"81","author":"S Turken","year":"1989","unstructured":"Turken S, Siris E, Seldin D, Flaster E, Hyman G, Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst. 1989;81:1086\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"13907_CR25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/1097-0142(19840215)53:4<853::AID-CNCR2820530406>3.0.CO;2-M","volume":"53","author":"A Gotfredsen","year":"1984","unstructured":"Gotfredsen A, Christiansen C, Palshof T. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer. 1984;53:853\u20137.","journal-title":"Cancer"},{"key":"13907_CR26","doi-asserted-by":"crossref","first-page":"100355","DOI":"10.1016\/j.jbo.2021.100355","volume":"28","author":"K Waqas","year":"2021","unstructured":"Waqas K, Lima Ferreira J, Tsourdi E, Body J-J, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol. 2021;28:100355.","journal-title":"J Bone Oncol"},{"key":"13907_CR27","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","volume":"22","author":"A Sverrisd\u00f3ttir","year":"2004","unstructured":"Sverrisd\u00f3ttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004;22:3694\u20139.","journal-title":"J Clin Oncol"},{"key":"13907_CR28","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, K\u00e4ssmann H, Piswanger-S\u00f6lkner JC, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9:840\u20139.","journal-title":"Lancet Oncol"},{"key":"13907_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx141","author":"H Goldvaser","year":"2018","unstructured":"Goldvaser H, Barnes TA, \u0160eruga B, Cescon DW, Oca\u00f1a A, Ribnikar D, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018. https:\/\/doi.org\/10.1093\/jnci\/djx141.","journal-title":"J Natl Cancer Inst"},{"key":"13907_CR30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1759720X18759291","volume":"10","author":"OL Tseng","year":"2018","unstructured":"Tseng OL, Spinelli JJ, Gotay CC, Ho WY, McBride ML, Dawes MG. Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2018;10:71\u201390.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"13907_CR31","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body J-J, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31:1650\u201363.","journal-title":"Ann Oncol"},{"key":"13907_CR32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.eprac.2022.12.003","volume":"29","author":"AE Kearns","year":"2023","unstructured":"Kearns AE. Managing bone health in breast cancer. Endocr Pract. 2023;29:408\u201313.","journal-title":"Endocr Pract"},{"key":"13907_CR33","doi-asserted-by":"crossref","first-page":"971","DOI":"10.6004\/jnccn.2006.0082","volume":"4","author":"RW Carlson","year":"2006","unstructured":"Carlson RW, Hudis CA, Pritchard KI, National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology, American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors, St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw. 2006;4:971\u20139.","journal-title":"J Natl Compr Canc Netw"},{"key":"13907_CR34","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353\u201361.","journal-title":"Lancet"},{"key":"13907_CR35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","volume":"20","author":"M Gnant","year":"2019","unstructured":"Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:339\u201351.","journal-title":"Lancet Oncol"},{"key":"13907_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-007-9774-6","volume":"111","author":"NL Henry","year":"2008","unstructured":"Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111:365\u201372.","journal-title":"Breast Cancer Res Treat"},{"key":"13907_CR37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jama.2018.8907","volume":"320","author":"DL Hershman","year":"2018","unstructured":"Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, et al. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial. JAMA. 2018;320:167\u201376.","journal-title":"JAMA"},{"key":"13907_CR38","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1002\/cncr.26230","volume":"117","author":"NL Henry","year":"2011","unstructured":"Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer. 2011;117:5469\u201375.","journal-title":"Cancer"},{"key":"13907_CR39","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1200\/OP.20.00113","volume":"16","author":"A Gupta","year":"2020","unstructured":"Gupta A, Henry NL, Loprinzi CL. Management of aromatase inhibitor-induced musculoskeletal symptoms. JCO Oncol Pract. 2020;16:733\u20139.","journal-title":"JCO Oncol Pract"},{"key":"13907_CR40","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0002-9378(97)70345-4","volume":"176","author":"JC Caillouette","year":"1997","unstructured":"Caillouette JC, Sharp CF Jr, Zimmerman GJ, Roy S. Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol. 1997;176:1270\u20135 (discussion 1275\u20137).","journal-title":"Am J Obstet Gynecol"},{"key":"13907_CR41","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1245\/s10434-022-12126-7","volume":"29","author":"V Huynh","year":"2022","unstructured":"Huynh V, Vemuru S, Hampanda K, Pettigrew J, Fasano M, Coons HL, et al. No one-size-fits-all: sexual health education preferences in patients with breast cancer. Ann Surg Oncol. 2022;29:6238\u201351. https:\/\/doi.org\/10.1245\/s10434-022-12126-7.","journal-title":"Ann Surg Oncol"},{"issue":"628","key":"13907_CR42","first-page":"e1","volume":"198","author":"RM Brotman","year":"2008","unstructured":"Brotman RM, Ghanem KG, Klebanoff MA, Taha TE, Scharfstein DO, Zenilman JM. The effect of vaginal douching cessation on bacterial vaginosis: a pilot study. Am J Obstet Gynecol. 2008;198(628):e1-7.","journal-title":"Am J Obstet Gynecol"},{"key":"13907_CR43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jmf.2006.1209","volume":"10","author":"DO Ogbolu","year":"2007","unstructured":"Ogbolu DO, Oni AA, Daini OA, Oloko AP. In vitro antimicrobial properties of coconut oil on Candida species in Ibadan, Nigeria. J Med Food. 2007;10:384\u20137.","journal-title":"J Med Food"},{"key":"13907_CR44","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1089\/jmf.2012.0303","volume":"16","author":"M Shilling","year":"2013","unstructured":"Shilling M, Matt L, Rubin E, Visitacion MP, Haller NA, Grey SF, et al. Antimicrobial effects of virgin coconut oil and its medium-chain fatty acids on Clostridium difficile. J Med Food. 2013;16:1079\u201385.","journal-title":"J Med Food"},{"key":"13907_CR45","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/09513591003632258","volume":"26","author":"N Biglia","year":"2010","unstructured":"Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010;26:404\u201312.","journal-title":"Gynecol Endocrinol"},{"key":"13907_CR46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","volume":"18","author":"RJ Santen","year":"2015","unstructured":"Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18:121\u201334.","journal-title":"Climacteric"},{"key":"13907_CR47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","volume":"135","author":"I Le Ray","year":"2012","unstructured":"Le Ray I, Dell\u2019Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135:603\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"13907_CR48","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","volume":"114","author":"S Cold","year":"2022","unstructured":"Cold S, Cold F, Jensen M-B, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: A Danish observational cohort study. J Natl Cancer Inst. 2022;114:1347\u201354.","journal-title":"J Natl Cancer Inst"},{"key":"13907_CR49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/joe.1.06264","volume":"187","author":"F Labrie","year":"2005","unstructured":"Labrie F, Luu-The V, B\u00e9langer A, Lin S-X, Simard J, Pelletier G, et al. Is dehydroepiandrosterone a hormone? J Endocrinol. 2005;187:169\u201396.","journal-title":"J Endocrinol"},{"key":"13907_CR50","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00520-017-3878-2","volume":"26","author":"DL Barton","year":"2018","unstructured":"Barton DL, Sloan JA, Shuster LT, Gill P, Griffin P, Flynn K, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26:643\u201350.","journal-title":"Support Care Cancer"},{"key":"13907_CR51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.2017.75.8995","volume":"36","author":"J Carter","year":"2018","unstructured":"Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice guideline adaptation of Cancer Care Ontario Guideline. J Clin Oncol. 2018;36:492\u2013511.","journal-title":"J Clin Oncol."},{"key":"13907_CR52","first-page":"CD007291","volume":"2014","author":"T Miles","year":"2014","unstructured":"Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev. 2014;2014:CD007291.","journal-title":"Cochrane Database Syst Rev"},{"key":"13907_CR53","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/AOG.0000000000003262","volume":"133","author":"ES Rubin","year":"2019","unstructured":"Rubin ES, Deshpande NA, Vasquez PJ, Kellogg Spadt S. A clinical reference guide on sexual devices for obstetrician-gynecologists. Obstet Gynecol. 2019;133:1259\u201368.","journal-title":"Obstet Gynecol"},{"key":"13907_CR54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.maturitas.2019.03.002","volume":"125","author":"J Mercier","year":"2019","unstructured":"Mercier J, Morin M, Zaki D, Reichetzer B, Lemieux M-C, Khalif\u00e9 S, et al. Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: a single-arm feasibility study. Maturitas. 2019;125:57\u201362.","journal-title":"Maturitas"},{"key":"13907_CR55","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/GME.0000000000001782","volume":"28","author":"X Jiang","year":"2021","unstructured":"Jiang X, Bossert A, Parthasarathy KN, Leaman K, Minassian SS, Schnatz PF, et al. Safety assessment of compounded non-FDA-approved hormonal therapy versus FDA-approved hormonal therapy in treating postmenopausal women. Menopause. 2021;28:867\u201374.","journal-title":"Menopause"},{"issue":"29","key":"13907_CR56","first-page":"767","volume":"2022","author":"\u201cThe 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel","year":"2022","unstructured":"\u201cThe 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;2022(29):767\u201394.","journal-title":"Menopause"},{"key":"13907_CR57","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jama.2021.14892","volume":"326","author":"FG Li","year":"2021","unstructured":"Li FG, Maheux-Lacroix S, Deans R, Nesbitt-Hawes E, Budden A, Nguyen K, et al. Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial. JAMA. 2021;326:1381\u20139.","journal-title":"JAMA"},{"key":"13907_CR58","doi-asserted-by":"crossref","first-page":"e2255697","DOI":"10.1001\/jamanetworkopen.2022.55697","volume":"6","author":"E Mension","year":"2023","unstructured":"Mension E, Alonso I, Angl\u00e8s-Acedo S, Ros C, Otero J, Villarino \u00c1, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial. JAMA Netw Open. 2023;6:e2255697.","journal-title":"JAMA Netw Open"},{"key":"13907_CR59","unstructured":"FDA News Release. Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to safeguard women\u2019s health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for \u201cvaginal rejuvenation\u201d. 30 July 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims. Accessed 2 May 2023."},{"key":"13907_CR60","unstructured":"FDA\u2019s Manufacturer and User Facility Device Experience (MAUDE) online database. https:\/\/www.accessdata.fda.gov. Accessed 2 May 2023."},{"issue":"16 Suppl","key":"13907_CR61","doi-asserted-by":"crossref","first-page":"e24048","DOI":"10.1200\/JCO.2022.40.16_suppl.e24048","volume":"40","author":"S Satish","year":"2022","unstructured":"Satish S, Pon F, Calfa C, Perez A, Rojas KE. Characterizing genitourinary exam disruptions in women presenting to a sexual health after cancer program. J Clin Oncol. 2022;40(16 Suppl):e24048.","journal-title":"J Clin Oncol"},{"key":"13907_CR62","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/jcpt.12563","volume":"42","author":"DM Stevens","year":"2017","unstructured":"Stevens DM, Weems JM, Brown L, Barbour KA, Stahl SM. The pharmacodynamic effects of combined administration of flibanserin and alcohol. J Clin Pharm Ther. 2017;42:598\u2013606.","journal-title":"J Clin Pharm Ther"},{"key":"13907_CR63","first-page":"325","volume":"12","author":"AH Clayton","year":"2016","unstructured":"Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health. 2016;12:325\u201337.","journal-title":"Womens Health"},{"key":"13907_CR64","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/AOG.0000000000003500","volume":"134","author":"SA Kingsberg","year":"2019","unstructured":"Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134:899\u2013908.","journal-title":"Obstet Gynecol"},{"key":"13907_CR65","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.fertnstert.2013.08.006","volume":"100","author":"EZ Latif","year":"2013","unstructured":"Latif EZ, Diamond MP. Arriving at the diagnosis of female sexual dysfunction. Fertil Steril. 2013;100:898\u2013904.","journal-title":"Fertil Steril"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13907-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13907-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13907-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T14:05:15Z","timestamp":1694441115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13907-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["13907"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13907-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no disclosures directly related to this work, however there are disclosures outside this work. Kristin Rojas reports the following relationships: consultant for Merck and Roche Diagnostic Solutions; and speaker's honoraria from Pacira Pharmaceuticals. Laura M. Spring declares the following relationships: consultant\/advisory board for Novartis, Puma, G1 Therapeutics, Daiichi Pharma, and Astra Zeneca; institutional research support from Phillips, Merck, Genentech, Gilead, and Eli Lilly. Liz O\u2019Riordan is not affiliated with an institution; she is the author of \u201cUnder the Knife\u201d and co-author of \u201cThe Complete Guide to Breast Cancer: How to Feel Empowered and Take Control\u201d. She is a paid consultant, writer and speaker (liz.oriordan.co.uk). Anna Weiss reports the following relationships: advisory board for Merck and Myriad; and institutional research support from Myriad.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}